AAA514

DRUG2 trials

Sponsors

Novartis Pharma AG, Odense University Hospital

Conditions

Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC)Metastatic Breast Carcinoma (BC)Primary breast cancerRecurrent or metastatic non-small cell lung cancer (NSCLC)

Phase 2

LuMIERE: A Phase 1/2, Multicenter, Open label, Non randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu FAP 2286 in Participants with an Advanced Solid Tumor

RecruitingCTIS2023-508995-12-01

Novartis Pharma AGLocally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC), Metastatic Breast Carcinoma (BC), Recurrent or metastatic non-small cell lung cancer (NSCLC)

Start: 2025-12-24Target: 36Updated: 2026-01-19

[⁶⁸Ga]Ga-HKG301 PET/CT for staging and restaging patients with primary breast cancer: a phase II study (FAPILOUS)

Not yet recruitingCTIS2025-521324-29-00

Odense University HospitalPrimary breast cancer

Target: 65Updated: 2026-08-14